文献速递神经肿瘤

低级别胶质瘤放疗或替莫唑胺治疗后的记忆功能:EORTC 22033-26033相关分析

Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
PubMed 文献 · Neuro Oncol · 2021-01-01

本研究基于EORTC 22033-26033研究,对98例高危低级别胶质瘤患者(53例放疗,46例替莫唑胺)使用视觉词语学习测验评估记忆功能。结果显示两组基线记忆无差异,随访中两组即刻回忆和总回忆均有改善,放疗组改善延迟,但放疗剂量体积与记忆功能无关。结论认为治疗后第一年放疗相比替莫唑胺化疗未显示对记忆功能的有害影响。

要点

  • 高危低级别胶质瘤患者放疗后第一年记忆功能未显示比替莫唑胺化疗更差。
  • 两组患者即刻回忆和总回忆随时间改善,放疗组改善出现延迟。
  • 记忆功能与放疗总剂量、临床或计划靶区体积无关。

核心结论

  • 在高危低级别胶质瘤患者中,治疗后第一年放疗相比替莫唑胺化疗未显示对记忆功能的有害影响。

研究设计与样本

  • EORTC 22033-26033研究的辅助分析,使用视觉词语学习测验在基线及每6个月评估记忆功能,统计分析最低依从性设为60%。
  • 共98例患者纳入神经心理评估(53例放疗,46例替莫唑胺)。

主要发现

  • 12个月时依从性降至66%,分析限制于基线、6个月和12个月。
  • 基线时两组在记忆功能、性别、年龄或教育水平上无差异。
  • 随时间推移,两组患者即刻回忆(P=0.017)和总回忆(P<0.001)均有改善,但放疗组改善延迟(组×时间交互P=0.011)。
  • 记忆功能与放疗总剂量、临床或计划靶区体积无关。

临床怎么用

  • 对于高危低级别胶质瘤患者,选择放疗或替莫唑胺化疗时,第一年内记忆功能损害不是决策的主要区分因素。

局限性

  • 12个月时依从性下降至66%,限制了长期随访分析。
  • 分析仅基于98例患者,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: EORTC study 22033-26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or temozolomide (TMZ) chemotherapy alone as primary treatment. Considering the potential long-term deleterious impact of RT on memory functioning, this study aims to determine whether TMZ is associated with less impaired memory functioning. METHODS: Using the Visual Verbal Learning Test (VVLT), memory functioning was evaluated at baseline and subsequently every 6 months. Minimal compliance for statistical analyses was set at 60%. Conventional indices of memory performance (VVLT Immediate Recall, Total Recall, Learning Capacity, and Delayed Recall) were used as outcome measures. Using a mixed linear model, memory functioning was compared between treatment arms and over time. RESULTS: Neuropsychological assessment was performed in 98 patients (53 RT, 46 TMZ). At 12 months, compliance had dropped to 66%, restricting analyses to baseline, 6 months, and 12 months. At baseline, patients in either treatment arm did not differ in memory functioning, sex, age, or educational level. Over time, patients in both arms showed improvement in Immediate Recall (P = 0.017) and total number of words recalled (Total Recall; P < 0.001, albeit with delayed improvement in RT patients (group by time; P = 0.011). Memory functioning was not associated with RT gross, clinical, or planned target volumes. CONCLUSION: In patients with high-risk low-grade glioma there is no indication that in the first year after treatment, RT has a deleterious effect on memory function compared with TMZ chemotherapy.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Klein M, Drijver AJ, van den Bent MJ, et al. Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033. Neuro Oncol. 2021. PMID: 33130890. doi:10.1093/neuonc/noaa252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。